An International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Ganitumab (Primary) ; Exemestane; Fulvestrant
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Amgen
- 12 Feb 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 03 Jul 2012 Planned number of patients changed from 150 to 156 as reported by European Clinical Trials Database record.
- 25 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History